Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements

Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements
Upstream Bio, Inc. posts trial results

Upstream Bio, Inc. reported new responder analyses from its Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at EAACI2026.

The results indicate that most participants receiving the treatment achieved clinically meaningful improvements across key endpoints, underscoring the potential of verekitug in this patient population. The data presentation highlights ongoing efforts to address unmet medical needs in CRSwNP. Upstream Bio, Inc. continues to evaluate verekitug in clinical trials as part of its research portfolio.

Upstream Bio, Inc. has increased industry visibility in recent months. CEO Rand Sutherland was scheduled to speak at the Goldman Sachs Annual Global Healthcare Conference via live webcast. The company also planned a fireside chat at a healthcare event in Miami earlier this month.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.